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Abstract (240 words) 
Background: Parkinson’s disease is heterogeneous, both in terms of motor symptoms and mood. 
Identifying associations between phenotypic variants of motor and mood subtypes may provide clues to 
understand mechanisms underlying mood disorder and symptoms in Parkinson’s disease. 
Methods: 513 patients were assessed using the Hospital Anxiety and Depression Scale, and separately 
classified into anxious, depressed and anxious-depressed mood classes based on latent class analysis of 
a semi-structured interview. Motor subtypes assessed related to age of onset, rate of progression, 
presence of motor fluctuations, lateralization of motor symptoms, tremor dominance and the presence of 
postural instability and gait symptoms and falls. 
Results: The directions of observed associations tended to support previous findings with the exception 
of lateralization of symptoms, where there were no consistent or significant results. Regression models 
examining a range of motor subtypes together indicated increased risk of anxiety in patients with 
younger age of onset and motor fluctuations. In contrast, depression was most strongly related to axial 
motor symptoms. Different risk factors were observed for depressed patients with and without anxiety, 
suggesting heterogeneity within Parkinson’s disease depression.  
Conclusion: Such association data may suggest possible underlying common risk factors for motor 
subtype and mood. Combined with convergent evidence from other sources, possible mechanisms may 
include cholinergic system damage and white matter changes contributing to non-anxious depression in 
Parkinson’s disease, while situational factors related to threat and unpredictability may contribute to the 
exacerbation and maintenance of anxiety in susceptible individuals. 
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Introduction 
Depression and anxiety are common and clinically important features of Parkinson’s Disease (PD). 
They can precede the onset of the motor symptoms[1;2] suggesting that Lewy-related and other 
pathology in selectively vulnerable structures may contribute to both motor and non-motor features.[3] 
Pathological data has suggested greater neuronal loss and gliosis in catecholaminergic areas of the brain 
(specifically, the locus coeruleus, dorsal vagus nerve and substantia nigra, pars compacta) in depressed 
patients,[4] while in vivo imaging studies suggest possible associations with both serotinergic and 
noradrenergic systems [5] and white matter abnormalities.[6] The presence and severity of depression 
and anxiety has no linear relation with disease duration and is either unrelated (or only modestly 
associated) with the severity of the motor symptoms,[7] observed in patients with early, mild disease as 
well as those with more advance symptoms.[8] This implies that any association between depression, 
anxiety and motor symptoms does not directly reflect common nigrostriatal pathology and fronto-
striatal pathophysiology.  
PD is a complex and variable disease with distinct clinical phenotypic subtypes involving both motor 
and non-motor features.[9] Depression has been linked to the akinetic-rigid form of PD compared to 
patients with a tremor dominant profile [10-13], and in patients with postural instability and gait 
disturbance (PIGD) particularly falls, versus those with a non-PIGD profile [13-16]. Depression has 
also been associated with more rapid progression [10;17;18], and with motor complications of therapy 
[15;19] although not in all studies.[11;14;20] There is also some evidence that patients with a younger 
age at disease onset show increased risk of depression [17;19;21] although other studies have found 
either no such association or even shown increased risk with later onset [10;11;14;15;22]. Finally, an 
association between depression and right sided motor asymmetry has been suggested [21;23;24] but not 
confirmed in all studies.[25;26]  
For anxiety, associations with the akinetic-rigid or PIGD motor phenotype are few and inconsistent 
[12;15;27] while there is no evidence regarding rate of disease progression and only a single negative 
report relating to lateralization of motor symptoms.[28] The strongest evidence emerging is an 
association between anxiety and young age of onset [15;20;28-30] and the presence of motor 
complications of treatment.[15;28-31]  
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The present study assessed, in a large sample of patients, a range of clinical and motor features 
suggested by previous research to be associated with depression and/or anxiety. Using a regression 
approach we aimed to determine the relative (rather than individual) significance of these often 
interdependent factors, providing better clues to guide research and improved management  
 
Subjects and Methods 
Patients with a diagnosis of PD were recruited from specialist movement disorder and care of the 
elderly clinics as described elsewhere.[32] Self-reported depressive and anxiety symptoms were 
assessed using the Hospital Anxiety and Depression Scale (HADS).[33] A subscale score of ≥11 on the 
HADS was taken to indicate significant depressive or anxiety symptoms. Phenomenological data 
relating to depression and anxiety were collected by trained staff using a semi-structured interview, the 
Geriatric Mental State, designed and validated for use in older adults including patients with dementia 
[34]. Based on a Latent Class Analysis (LCA) of these data patients were categorised into four classes: 
‘Anxious-Depressed’ (8.6%), ‘Depressed’ (9.0%) and ‘Anxious’ (22%), while a fourth group (60.4%) 
comprised patients with low levels of psychiatric symptomatology [32]. Activities of daily living and 
motor function were assessed using the UPDRS parts II and III [35] and disease stage with the Hoehn 
and Yahr Scale.[36] Cognitive function was assessed using the Addenbrooke’s Cognitive Examination-
Revised (ACE-R)[37] which incorporates the Mini-Mental State Examination (MMSE).[38] Levodopa 
equivalent daily dose (LEDD) was calculated as described elsewhere.[39] 
Classification of Parkinson subtypes was based on previously reported studies. Younger age of onset 
was defined as onset of motor symptoms before the age of 55 years. Motor subtype was identified as 
PIGD or tremor dominant/indeterminate [40] and as tremor dominant or non-tremor dominant (akinetic-
rigid).[10] Patients were also classified according to whether they reported postural instability and falls 
(PIF) (UPDRS Part II item 13>1) and freezing of gait (FOG) (UPDRS Part II item 14>1).[16] Rate of 
disease progression was estimated from cross-sectional data by dividing the UPDRS-III total by 
duration of disease since diagnosis in years [10] and dichotomized on the sample median. Motor 
complications of treatment (present or absent) were defined as motor fluctuations and/or sudden onset 
fluctuations (UPDRS Part IV). Lateralization was determined from the left and right side motor 
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symptom scores on the UPDRS part III. The study was approved by the South East Research Ethics 
Committee (ref 07/MREC01/9). All participants gave written informed consent. 
 
Statistical analysis 
The clinical characteristics of the dichotomized subtypes were compared using parametric or non-
parametric ANOVA. These comparisons were not hypothesis or model testing and no correction was 
made for multiple comparisons. The p-values provide an indication of the strength of evidence 
supporting differences between subtypes comparable to previous reports. Continuous measures of 
anxiety and depression were compared between the dichotomized Parkinson subtypes using parametric 
parametric ANOVA, again for descriptive purposes, with age as a covariate where this was found to 
differ between subtypes. Three types of categorical data were compared (Fisher’s exact or tests or 
linear-by-linear association) with adjustment made for multiple comparisons (critical p=0.017). Logistic 
regression (forced entry method) was used to indentify predictors of categorical depression, anxiety 
(binary regression) and mood class (multinomial regression). Analyses were performed using PASW 
Statistics (Chicago, IL) Version 18. 
 
Results 
Sample details (N=513) are provided in Table 1. Table 2 shows the demographic and clinical 
characteristics according to Parkinson subtype while Table 3 shows the relationship between motor 
subtypes and mood. There was no significant relationship between lateralization of motor symptoms, 
depression and anxiety (in all instances p>0.10) and these results are not considered further. Patients 
with onset less than 55 years had higher mean HADS anxiety score and a higher proportion showed 
significant anxiety. The proportion of patients in the three mood classes also differed significantly with 
higher proportions of early onset patients in the two anxiety-related classes (Classes 1 and 3) while the 
older onset group was more frequent in the ‘depressed’ class (Class 2). Patients with either PIGD or 
non-tremor dominant subtypes were somewhat more depressed on the HADS. The PIGD or non-tremor 
dominant subtypes were more strongly represented in all three of the empirical mood classes compared 
to the non-PIGD or tremor dominant patients. Patients with either FOG or PIF were more depressed and 
anxious as assessed by the HADS. Those with FOG also showed increased levels of significant 
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depression and anxiety, with the rate of depression almost four times that of patients without FOG. 
Patients with motor fluctuations were more depressed and anxious on the HADS, with increased rates of 
significant depression and anxiety and were more strongly represented in all three affective classes but 
particularly in the anxiety-related ones. Finally, patients with faster rate of progression were slightly 
more depressed and anxious than those with slower rates of progression, but did not differ in mood class 
distribution. 
Logistic regression was used to assess which Parkinson subtype(s) best predicted the presence of 
depression (HADS depression ≥11), anxiety (HADS anxiety≥11) (N=490) or mood class (N=512) 
(Table 4). The PIGD/Non-PIGD and Non-Tremor/Tremor classifications produced similar results and 
only the former is reported in the final model (Table 4). The full set of dichotomized predictors was: age 
of onset (‘early’ <55, ‘late’ ≥55), motor subtype (PIGD, non-PIGD), PIF subtype (present, absent), 
FOG subtype (present, absent), motor fluctuations (present, absent) and rate of progression (‘fast’, 
‘slow’) with the second category as the reference in each case. All potential predictors were entered into 
the models. Most associations were positive (predictor associated with worst mood) in agreement with 
previous findings. Significant predictors of HADS depression were FOG subtype and the presence of 
motor fluctuations. HADS anxiety was predicted by younger age of onset and rapid disease progression. 
The three mood classes were analysed in a multinomial model with class 4 (no prominent symptoms) as 
the reference category. Young onset, PIGD and FOG subtypes and motor fluctuations were significant 
in the overall model. Membership of the anxious-depressed class (class 1) was specifically predicted by 
young onset, PIF subtype and motor fluctuations. Anxiety (without depression) (class 3) was predicted 
by young onset, PIGD and motor fluctuations. Finally, depression (without anxiety) (class 2) was 
predicted only by PIDG subtype.  
Because of the associations between some of the predictors and cognitive status (Table 2), secondary 
analyses were carried out to assess whether cognitive impairment (ACE-R <83) added to the three 
models described above. Impairment was a significant independent predictor of HADS depression (OR 
= 1.99, 1.08 – 3.69, p = 0.027) but not HADS anxiety (OR = 0.73, 0.42 – 1.28, p = 0.282). Similarly, 
cognitive impairment predicted membership of the Depression class (OR = 3.06, 1.05 – 8.92, p=0.041) 
but not the Anxious-Depressed (OR = 1.63, 0.59 – 4.45, p = 0.35) or Anxious classes (OR = 0.63, 0.26 
– 1.51, p = 0.295). 
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Discussion  
The present study confirms the significance of some but not all of the features of PD shown previously 
to be associated with depression and expands our knowledge in relation to anxiety. The univariate 
results lend some support for an association between younger age of onset and depression, but much 
more strongly for anxiety. In the regression analyses, even with other predictors in the model, age of 
onset below 55 years (mean 46.7) was strongly associated with the presence of clinically significant 
anxiety and membership of both anxiety-related classes. The profile of anxiety in these classes [32] is 
similar to that seen in generalized anxiety disorder (GAD). Such results are consistent with emerging 
evidence [15;20;28-30] and point to a specific risk an anxiety and anxiety disorder in such patients. The 
present and previous findings relating to depression are more equivocal. Heterogeneity within PD 
depression may account for some of the inconsistency if younger anxious-depressed patients, 
representing a distinct phenotypic subtype of depression, are combined in the same sample with older 
depressed patients without anxiety.[32]  
Reasons for an association between anxiety and younger age of onset are currently unclear. Early onset 
of PD is associated with higher rates of some known genetic mutations. Psychiatric disturbance 
including anxiety has been reported in two parkin gene mutations (PARK2 and PARK7) [41] although 
the rates may be no higher than in patients without parkin mutations.[42;43] At present, the genetics of 
anxiety disorder is uncertain although there appear to be links to the genetics of lifetime trait 
neuroticism.[44] The onset of GAD can also be associated with traumatic and stressful life events in 
such susceptible individuals, particularly events involving loss or danger.[45] While PD can be a 
chronic stressor for all patients, the loss or threat of loss of social, family and occupational function is 
typically far greater in those developing the disease earlier in life. This offers one plausible mechanism 
for the observed association between anxiety and young age of onset.[46] The findings of the present 
study linking HADS anxiety to faster rate of motor progression may also be mediated by greater 
psychosocial stress and loss, rather than a direct association with pathophysiological progression. This 
latter finding, however, was not replicated in the two anxiety-related mood classes and so should be 
interpreted with caution. Previous studies have also suggested greater degree of depression in patients 
with more rapidly progressive disease,[10;17;18] although this was not strongly supported by the 
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present results. Examination of longitudinal data from the present cohort will help disentangle the 
potential contribution of rate of progression to risk of depression and anxiety. 
Motor complications of treatment increase in prevalence with disease duration and with the duration 
and dose of antiparkinsonian treatment. In a prevalent cohort, younger age of onset is typically 
associated with longer duration of disease and treatment and hence a high rate of treatment related 
motor complications.[41] However, the present study suggests that motor fluctuations make a 
substantial independent contribution to the prediction of anxiety beyond age of onset alone. Some 
patients report marked anxiety restricted to the off-periods, perhaps representing a specific 
dopaminergic or dopa-mediated ‘mood-off’ phenomenon.[47] However, the present study focused on 
anxiety symptoms present more generally over preceding weeks and not simply acute anxiety states 
synchronised with motor status. The pathophysiological basis of motor fluctuations remains unclear and 
therefore hard to link to possible shared biological mechanisms with anxiety. However, a non-biological 
explanation may be found in the fact that motor-fluctuations are often unpredictable and add 
significantly to the lack of control that some patients perceive in their day-to-day lives. Intolerance of 
uncertainty is a trait cognitive bias common in anxiety disorders and particularly GAD. It is associated 
with high levels of worry and catastrophic predictions plus counter-productive coping behaviour.[48] 
Patients susceptible to motor fluctuations and who find the experience distressing report ‘testing’ their 
motor function or ‘scanning’ for signs of an impending off-period that would require a dose of 
medication. Such attentional focus on, and attempt to control, an often unpredictable event typically 
serves to maintain state anxiety rather than reduce it. Motor fluctuations may therefore provide a 
particularly salient stressor that exacerbates anxiety in already anxious individuals rather than reflecting 
a specific pathophysiological association. 
Consistent with previous studies, the univariate data suggests that patients with a tremor-dominant 
motor subtype tended to be less depressed and to be under-represented in each of the three mood-
classes. Such patients tended also to have shorter disease duration, less severe motor symptoms and less 
cognitive impairment (Table 2). The regression analysis focussed on the overlapping distinction 
between PIGD and non-PIGD subtypes, and the two subclasses of fallers, those with postural instability 
(PIF) and those with freezing of gait (FOG). Previous research [13-16] has indicated an association 
between such factors and depression, findings that were partially replicated in the present results. Axial 
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symptoms are typically unresponsive to dopaminergic medication and therefore presumed to reflect 
extra-nigral pathophysiology. By association, the same or parallel mechanisms may also contribute to 
non-motor symptoms including cognitive impairment and depression, shown to be associated, including 
in the present sample. For example, axial motor symptoms have been linked to loss of pedunculopontine 
nucleus (PPN) cholinergic neurones.[49] The role of cortical cholinergic loss in PD dementia is well 
established [50] and there is in vivo evidence for similar loss related to the severity of depressive 
symptoms in both demented and non-demented patients, as well as thalamic loss in fallers.[51] Arguing 
against a role for the cholinergic system in depression is the lack of robust evidence for a significant 
impact of cholinesterase inhibitors on mood in PD (e.g. [52]), although, to date, there have been no 
randomized trials with depression as a primary outcome. A second possible mechanism underpinning an 
association between axial symptoms and depression is white matter change. White matter damage is a 
significant predictor of gait problems and falls in the elderly [53] and is also strongly associated with 
depression and cognitive impairment.[54] In PD, microstructural white matters changes are similarly 
associated with both axial motor and cognitive symptoms [55] while recent in vivo studies report 
increased white matter changes in cortico-limbic and medial thalamic areas in depressed patients.[6;56] 
In contrast to the evidence relating motor subtype to depression in PD, there is limited and inconsistent 
evidence for an association with anxiety. [12;15;27] Pontone and colleagues examined the motor 
characteristics of anxious versus non-anxious people with PD and, although they did not specifically use 
a motor subtype classification, they did not find any difference in motor features between groups.[30] 
The present results do not provide any robust evidence for an association between postural instability 
and anxiety, although in individual patients fear of falling may be a significant source of concern and 
contribute to activity limitation and social avoidance.[57;58] Already anxious patients who develop 
postural instability or who then experience falls may well become more anxious in response to this 
unpredictable and potentially harmful problem. Such specific anxiety is known to adversely affect 
anticipatory postural control further strengthening the relationship.[59] In patients with motor 
fluctuations, anxiety may also contribute to the escalation in medication use observed in some patients 
as they seek to ward off impending or anticipated off-periods, or even prompt requests for surgical 
interventions as a way of seeking to control unpredictable and distressing motor symptoms. 
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Although the largest study of its type, some limitations of the present study should be acknowledged. 
The HADS, although a valid measure of depression and anxiety in PD does not capture all of the 
symptoms related to syndromal disorder. Second, the absence of a comparison group makes it 
impossible to assess the impact of age independent of disease factors. 
In conclusion, the present results reinforce and extend our understanding of the clinical associations 
between parkinsonian motor subtypes, depression and anxiety, and support the importance of 
considering heterogeneity in exploring possible aetiological models. The reported associations do not 
imply any single causal mechanism. Depression and anxiety are multifactorial with complex and 
variable factors probably contributing to both onset and symptom maintenance. There is growing 
evidence for the role of monoamine systems in PD depression.[5] However, when combined with 
evidence from other sources, the present association findings suggest a possible contribution of the 
cholinergic system and white matter change, at least in older non-anxious depressed patients. While 
specific neurochemical changes may also contribute to trait anxiety in PD, perhaps predating the onset 
of the motor symptoms, the evidence reported here is also consistent with an additional role for 
situational (state) factors such as the threat posed by the disease (e.g. to younger patients) and its 
symptoms (e.g. motor fluctuations) and their often inherent unpredictability. Such results can have 
direct clinical relevance. First, they show the potential importance on non-biological factors in driving, 
maintaining or exacerbating anxiety in biologically susceptible individuals. Second, anxiety may 
interact negatively with a patient’s motor state and way they seek to manage their symptoms. Third a 
broader bio-psychosocial model may usefully guide the evaluation of psychological treatments using 
methods already used to treat similar anxiety symptoms in non-neurological populations. 
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Table 1  Demographic and clinical characteristics (N = 513)  
 
Variable Mean (SD) 
/Median*/% 
Range 
Demographic and social  Age (Years) 67.9 (10.3) 32 - 94  Gender (% Male) 65.1% - 
Parkinson’s disease history, symptoms and treatment  Age at PD onset (Years) 61.0 (12.1) 13 – 92  Duration on PD (Years) 5.0*  0 - 39  UPDRS-III (Total score) 26.4 (12.0) 4 - 78  LEDD (mg/day) 600* 0 - 7565  Hoehn and Yahr stages I/II-III/IV-V (%) 12.6/80.2/7.2% -  Rate of progression (median) 5.25 1 - 31 
Cognitive function    ACE-R (Total score) 86.4 (10.7) 30 - 100  ACE-R ≤83 (%) 29.7% -  MMSE (Total score) 27.9 (2.5) 16 - 30 
Depression and Anxiety  HADS-Depression 6.3 (3.7) 0 – 17  HADS-Depression ≥11 (%) 13.0% -  HADS-Anxiety 7.2 (4.5) 0 – 20  HADS-Anxiety ≥11 (%) 22.0% -  HADS-Total score 13.5 (7.2) 0 - 37 
MDS-11-0725 (Revision) 
Table 2 Parkinson subtypes: demographic and clinical characteristics  
 
Subtype N Age (years) Gender  
 
Age of onset 
of PD (years) 
PD Duration 
(years) 
UPDRS(III) 
Total 
LEDD (mg/day) ACE-R Total 
  Mean (SD) (% Male) Mean (SD) Median  
(min-max) 
Mean (SD) Median  
(min-max) 
Mean (SD) 
Age of onset          <55 157 57.7 (8.3)*** 63.7 46.7 (6.6)*** 10.0 (0 – 39)*** 26.4 (13.2) 800 (0 – 3641)*** 89.0 (10.2)***  ≥55 356 72.4 (7.6) 65.7 67.3 (7.9) 4.0 (0 – 23) 26.6 (11.4) 500 (0 – 7565) 85.3 (10.7) 
Motor phenotype (a)          PIGD 369 68.6 (9.9)* 63.4 61.0 (12.1) 6.0 (0 – 39)*** 27.9 (11.5)*** 640 (0 – 7565) *** 85.5 (11.1)**  Non-PIGD 144 66.1 (11.3) 69.4 61.0 (12.1) 3.5 (0 – 28) 23.2 (12.6) 430 (0 – 3169) 88.7 (8.9) 
Motor phenotype (b)          Non-Tremor 420 68.2 (9.9) 63.6 60.1 (12.2) 5.0 (0 – 39)*** 27.7 (11.5)*** 620 (0 – 7565)*** 85.9 (10.9)*  Tremor 93  66.5 (12.0) 72.0 61.3 (11.9) 3.0 (0 – 27) 21.4 (12.7) 420 (0 – 2960) 88.7 (9.3) 
Freezing of gait          Yes 75 67.3 (10.1) 72.0 56.1 (13.1)*** 10.0 (0 – 39)*** 35.5 (13.0)*** 800 (0 – 7565)*** 83.2 (11.6)**  No 438 68.0 (10.4) 63.9 61.8 (11.7) 4.0 (0 – 28) 25.0 (11.1) 575 (0 – 3641) 86.9 (10.4) 
Postural Instability/Falls         Yes 77 68.5 (9.7) 64.9 55.7 (13.9)*** 13.0 (0 – 39)*** 34.1 (11.8)*** 920 (210 – 2800)*** 81.4 (12.0)***  No 436 67.7 (10.5) 65.1 61.9 (11.5) 4.0 (0 – 28) 25.2 (11.5) 531 (0 - 7565) 87.3 (10.2) 
Motor fluctuation          Yes 138 64.4 (9.8)*** 59.4 54.3 (10.5)*** 10.0 (0 – 26)*** 29.2 (12.9)** 922 (100 - 7565)*** 87.2 (10.7)  No 375 69.1 (10.2) 67.2 63.4) (11.7) 4.0 (0 – 39) 25.6 (11.5) 495 (0 - 3641) 86.1 (10.6) 
Rate of progression          ‘fast’ 259 68.7 (11.1) 68.0 65.3 (11.5)*** 3.0 (0 – 13)*** 29.1 (11.0)*** 481 (377)*** 85.8 (10.5)  ‘slow’ 254 67.0 (9.4) 62.1 56.6 (11.1) 10.0 (1 – 39) 24.0 (12.4) 924 (694) 87.1 (10.7) 
 
* p<0.05, ** p<0.01, ***p<0.001 
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Table 3 Parkinson subtypes: relationship to depression, anxiety and mood class  
 
 HADS 
Depression 
total 
HADS 
Depression 
≥11 (%)  
HADS 
Anxiety 
total 
HADS 
Anxiety ≥11 
(%) 
Class 1 (%) 
‘Anxious-
Depressed’ 
Class 2 (%) 
‘Depressed’ 
Class 3 (%) 
‘Anxious’ 
Mood 
class 
signif. † 
Age of onset          <55 6.6 (3.9) 17.3 8.7 (4.7)*** 31.4* 17.8 6.4 32.5 **  ≥55 6.1 (3.5) 11.0 6.5 (4.2) 17.6 4.5 10.1 17.4  
Motor phenotype-a          PIGD 6.6 (3.6)* 14.6 7.5 (4.3) 23.1 9.2 11.4 24.4 *  Non-PIGD 5.3 (3.6) 9.2 6.5 (4.7) 19.1 6.9 2.8 16.0  
Motor phenotype-b           Non-Tremor 6.6 (3.6)* 14.2 7.4 (4.3) 22.9 9.3 10.0 24.3 *  Tremor 5.0 (3.6) 7.8 6.2 (4.9) 17.8 5.4 4.3 11.8  
Freezing of gait          Yes 8.9 (4.5)** 34.7** 8.8 (4.6)** 33.3* 21.3 17.3 16.0 **  No 5.8 (3.3) 9.3 6.9 (4.4) 20.0 6.4 7.5 23.1  
Postural Instability/Falls         Yes 7.8 (3.8)** 19.2 9.1 (4.7)** 31.5 22.1 14.3 24.7 **  No 6.0 (3.6) 12.0 6.9 (4.3) 20.3 6.2 8.0 21.6  
Motor fluctuations          Yes 7.3 (3.7)** 20.0* 8.5 (4.3)* 30.4* 15.9 10.9 33.3 **  No 5.9 (3.6) 10.4 6.7 (4.4) 18.8 5.9 8.3 17.9  
Rate of progression          ‘fast’ 6.6 (3.6)** 14.5 7.4 (4.6)** 25.2 8.1 9.7 18.5   ‘slow’ 6.0 (3.7) 11.3 7.0 (4.3) 18.5 9.1 8.3 25.7  
 
† Test of proportion of classes 1-3 across the two subtypes, Linear-by-Linear association 
For HADS depression and anxiety totals * p<0.05, ** p<0.01, ***p<0.001 
For HADS depression and anxiety ≥11 and mood class * p<0.017, ** p<0.003 
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Table 4 Predictors of significant depression and anxiety (HADS) and mood class (class 4 reference): results of logistic regression  
 
 
 
HADS  
Depression ≥11 
HADS  
Anxiety ≥11 Mood class 
Class 1  
‘Anxious-
Depressed’ 
Class 2  
‘Depressed’ 
Class 3  
‘Anxious’ 
Model fit χ2 (6)=37.20** χ2 (6)=29.30** χ2 (6)=109.2**    
Predictor OR (95% CI) OR (95% CI) 
Likelihood 
ratio test   OR (95% CI) OR (95% CI) OR (95% CI) 
 Young onset 1.58 (0.84 – 2.96) 2.33 (1.46 – 3.85)** ** 5.37 (2.50 – 11.52)** 0.88 (0.38 – 2.03) 2.52 (1.52 – 4.12)** 
 PIGD subtype 1.49 (0.73 – 3.02) 1.18 (0.69 – 1.99) ** 1.19 (0.52 – 2.74) 4.51 (1.55 – 13.16)* 1.94 (1.13 – 3.36)* 
 PIF subtype 0.72 (0.33 – 1.61) 1.27 (0.68 – 2.40)  2.95 (1.24 – 6.99)* 1.63 (0.69 – 3.83) 1.30 (0.65 – 2.62) 
 FOG subtype 5.00 (2.56 – 9.71)** 1.54 (0.83 – 2.85) * 2.07 (0.89 – 4.83) 2.09 (0.94 – 4.67) 0.57 (0.26 – 1.24) 
 Motor fluctuations 2.10 (1.17 – 3.79)* 1.58 (0.95 – 2.61) ** 2.49 (1.18 – 5.24)* 1.79 (0.85 – 3.76) 2.54 (1.52 – 4.24)** 
 Fast progression 1.77 (0.99 – 3.17) 2.25 (1.38 – 3.67) **  1.90 (0.90 – 4.00) 1.24 (0.63 – 2.44) 1.00 (0.62 – 1.62) 
 
OR = Odds ratio, 95% CI = 95% Confidence interval 
 
* p<0.017, ** p<0.003 
 
(NB: significance indicator for ‘Mood class’ indicates the contribution of the predictor in overall multinomial model; significance for individual classes 1-3 
indicates the contribution of the predictor to the contrast between that class and the reference ‘Healthy’ class)
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